Results 91 to 100 of about 11,874 (152)

International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges. [PDF]

Neurol Ther
Chan A, Alroughani R, Calabrese M, Havrdová EK, Obeidat AZ, Schmierer K, Andersson M, Bek L, Savarin C, Korich J, Bonsignore L, de Seze J.   +11 more
europepmc   +1 more source

Threshold-Dependent Discordance Between STRATIFY JCV™ and IMMUNOWELL™ Assays in Relapsing Multiple Sclerosis. [PDF]

Neurol Ther
Chisari CG, Crimì P, Spampinato G, Ferraro E, Alecci A, Lo Fermo S, Cimino V, Zappia M, Patti F.   +8 more
europepmc   +1 more source

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study. [PDF]

Front Neurol
Huygens S, Versteegh M, Berg-Hansen P, Bjelland SH, Holmøy T, Torkildsen Ø.   +5 more
europepmc   +1 more source

Assessing the value of oligoclonal band count in multiple sclerosis: insights from a large cohort analysis. [PDF]

Front Neurol
Jendretzky KF, Wurster U, Konen FF, Döring K, Friedrich JF, Nay S, Möhn N, Grote-Levi L, Hümmert MW, Sühs KW, Schwenkenbecher P, Gingele S, Skripuletz T.   +12 more
europepmc   +1 more source

Diminishing returns of disease-modifying treatment in older participants of multiple sclerosis clinical trials. [PDF]

Mult Scler
Strijbis E, Mostert J, D'Haeseleer M, Moral E, Brieva Ruiz L, Comtois J, Killestein J, Repovic P, McPherson T, Cutter G, Koch M.   +10 more
europepmc   +1 more source

Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses. [PDF]

Front Immunol
Curtin R, Velmurugu Y, Dibba F, Hao Y, Nyovanie S, Lopez A, Mieles D, Ng C, Perdomo K, Scott N, Lewin JB, Avila RL, Smrtka J, Patskovsky Y, Howard J, Silverman GJ, Krogsgaard M.   +16 more
europepmc   +1 more source

No association between the wearing-off effect and α4-integrin receptor saturation in natalizumab treated patients with relapsing-remitting multiple sclerosis. [PDF]

Neurotherapeutics
Freeman SA, Rual C, Biotti D, Lepetit M, Le Berre J, Ferrara K, Treiner E, Ciron J.   +7 more
europepmc   +1 more source

Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens. [PDF]

J Neurol
Konitsioti AM, Schweitzer F, Johannis W, Steffen F, Bittner S, Fink GR, Schroeter M, Warnke C.   +7 more
europepmc   +1 more source

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab. [PDF]

BMJ Neurol Open
Høgestøl EA, Brustad ÅW, Celius EG, Meling M, Berg-Hansen P, Kro GB, König M, Schanke Y, Halvorsen B, Warren DJ, Gehin JE, Bolstad N, Nygaard GO.   +12 more
europepmc   +1 more source

Systematic Review of Monoclonal Antibody Therapies in Relapsing Multiple Sclerosis: Comparator-Stratified Analysis of Relapse and Disability Outcomes. [PDF]

Med Sci (Basel)
Ciubotaru A, Grosu C, Maștaleru A, Constantinescu V, Alexa D, Covali R, Riscanu L, Bilcu RV, Cucu LE, Gațcan C, Socolov-Mihaita SA, Lăcătușu D, Crivoi F, Vamanu A, Patrascu A, Ignat EB.   +15 more
europepmc   +1 more source